Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients

Abstract

Background This study aimed to identify adverse events following the first three doses of COVID-19 vaccines in hemodialysis (HD) patients. Risk factors associated with postvaccination adverse events were explored. Methods Postvaccination adverse events in 438 HD patients who received 3 doses of COVID-19 vaccines were prospectively assessed. The adverse events among three doses were compared using generalized linear mixed models. Factors associated with adverse events were assessed with multivariate analyses. Results The vast majority of participants received Oxford/AstraZeneca ChAdOx1 as their first two doses and Moderna mRNA-1273 as their third dose. Overall, 79%, 50% and 84% of the participants experienced at least one adverse event after their first, second, and third doses, respectively. These adverse events were mostly minor, short-lived and less than 5% reported daily activities being affected. Compared with the first dose, the second dose caused a lower rate of adverse events. Compared with the first dose, the third dose elicited a higher rate of injection site reactions and a lower rate of systemic reactions. Multivariate analyses showed that every 10-year increase of age (odds ratio 0.67, 95% confidence intervals 0.57-0.79) was associated with decreased risk of adverse events, while female sex (2.82, 1.90-4.18) and arteriovenous fistula (1.73, 1.05–2.84) were associated with increased risk of adverse events. Compared with Oxford/AstraZeneca ChAdOx1, Moderna mRNA-1273 was associated with an increased risk of injection site reactions. Conclusions COVID-19 vaccination was well tolerated in HD patients. Age, sex, dialysis vascular access and vaccine types were associated with postvaccination adverse events.

Potent induction of humoral and cellular immunity after bivalent BA.4/5 mRNA vaccination in dialysis patients

“…As with previous vaccinations, patients either reported no adverse events or primarily local pain at the injection site. This is in line with previous reports of COVID-19 vaccine tolerability and also extends to other vaccine types 35 . Reactogenicity was significantly different from immunocompetent controls where more individuals reported local and/or systemic reactions that were most frequently pain at the injection site followed by fatigue.…”

Potent induction of humoral and cellular immunity after bivalent BA.4/5 mRNA vaccination in dialysis patients with and without history of SARS-CoV-2 infection

“…As with previous vaccinations, patients either reported no adverse events or primarily local pain at the injection site. This is in line with previous reports of COVID-19 vaccine tolerability and also extends to other vaccine types 43 . Reactogenicity was significantly different from immunocompetent controls where more individuals reported local and/or systemic reactions that were most frequently pain at the injection site followed by fatigue.…”

SARS-CoV-2-Specific Antibodies, B Cell and T Cell Immune Responses after ChAdOx1 nCoV-19 Vaccination in Solid Organ Transplant Recipients

“…AEs during the early period at 3-day and 7-day post-vaccination were reported to be mild, as demonstrated. The observed AE profile is like those reported in previous COVID-19 vaccine studies [27,28]. The most common AE reported in our study was injection site pain, reported by approximately half of SOT recipients who obtained vaccination.…”